Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

1. Low-risk MDS-A spotlight on precision medicine forHemaSphere · 2025
   Review
2. Lower-risk myelodysplastic syndromes: Current treatment options for anemia.EJHaem · 2022
   Review
3. Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.Oncotarget · 2017
   Article
4. Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.Blood research · 2014
   Article
5. Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.Mediterranean journal of hematology and infectious diseases · 2014
   Article

Corrections and comments

• Comment on
  An update on iron chelation therapy.2012

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as